Symbravo Shortage: What Providers and Prescribers Need to Know in 2026

Symbravo (meloxicam 20 mg / rizatriptan 10 mg), approved by the FDA on January 30, 2025, represents a meaningful addition to the acute migraine treatment landscape. Its dual-mechanism design — combining a MoSEIC-formulated NSAID with a rapid-acting triptan — offers superior efficacy over either agent alone in clinical trials. However, providers are increasingly encountering patient reports of difficulty filling prescriptions. This guide explains the root causes of those access challenges and provides actionable strategies to support your patients.

Clinical Overview: Why Symbravo Represents a New Approach

Symbravo's design is built around the temporal dynamics of migraine pathophysiology. Rizatriptan — the oral triptan with the fastest onset — reaches peak plasma concentration approximately 30 minutes post-dose, before CGRP peaks at around one hour post-onset. The MoSEIC meloxicam reaches peak plasma concentration between 45–60 minutes, addressing the prostaglandin E2 (PGE2) inflammatory surge that peaks at approximately two hours. By targeting two distinct pathways before they reach maximal expression, Symbravo is designed to intercept the migraine cascade more completely than monotherapy.

Key Phase 3 data points for clinical context:

MOMENTUM trial: In patients with inadequate response to prior acute treatments, Symbravo achieved 2-hour pain freedom in 19.9% vs. 6.7% with placebo (p<0.001). 77% did not require rescue medication within 24 hours.

INTERCEPT trial: In patients treating migraine at mild intensity, 85% did not require rescue medication within 24 hours.

EMERGE trial: In patients with prior inadequate response to oral CGRP inhibitors, 47.9% achieved 2-hour pain freedom with Symbravo vs. 1% with continued gepant use.

The Access Gap: Why Patients Are Having Trouble Filling Symbravo

Symbravo is not listed in an official FDA or ASHP drug shortage. The access barriers your patients face are structural, not supply-chain, issues:

1. Pharmacy Stocking Gaps

New brand-name drugs typically take 12–18 months to achieve consistent nationwide pharmacy stocking. Pharmacies stock based on local demand, and demand is still building for Symbravo. Smaller and independent pharmacies often do not stock it at all. Large chains (CVS, Walgreens, Walmart Pharmacy) have better availability. Patients presenting a prescription at an unstocked pharmacy without preparation will frequently be turned away.

2. Insurance Coverage Challenges

Coverage is one of the most significant barriers:

Medicare Part D: Most plans do not cover Symbravo. Formulary exceptions may be pursued but are difficult to obtain without strong documented clinical need.

Commercial/ACA plans: Coverage is limited. Prior authorization is frequently required. Step therapy requiring documented failure of at least one or two other triptans is common.

Medicaid: Most plans cover Symbravo, but prior authorization is typically required.

3. High Cash Price Without Coverage

At approximately $1,300–$1,420 for 9 tablets (roughly $125–$158 per tablet), the retail cash price of Symbravo is prohibitive for most patients without coverage. This drives high prescription abandonment rates at pharmacy counters.

Provider Strategies to Improve Patient Access

When prescribing Symbravo, the following proactive steps significantly improve the odds your patient fills the prescription:

A. Submit Prior Authorization Early

For commercial and Medicaid patients, submit prior authorization at the time of prescribing rather than waiting for a pharmacy rejection. Include documentation of:

Previous triptan trials and documented responses or failures

Migraine frequency, severity, and functional impact

Clinical rationale for dual-mechanism approach (e.g., inadequate response to monotherapy, need for fast sustained relief)

B. Direct Patients to the Savings Program

For commercially insured patients, the Symbravo On My Side Savings Program from Axsome Therapeutics can reduce out-of-pocket cost to as little as $10 for up to a 90-day supply. Have your front desk provide the number (866-496-2976) or include it in patient discharge materials. Note: This program is not available to Medicare or Medicaid patients.

C. Provide Samples When Available

Axsome Therapeutics sales representatives may provide physician samples. Samples allow patients to try Symbravo immediately and give time for PA processing or pharmacy ordering. Contact your Axsome representative to establish a sample supply.

D. Recommend Specific Pharmacies and Use Patient-Facing Tools

Direct patients to large chain pharmacies (CVS, Walgreens, Walmart Pharmacy) that are most likely to have Symbravo or be able to order it quickly. You can also recommend medfinder for providers — a service that calls pharmacies on behalf of patients to find which ones have a given medication in stock, delivering results via text message.

Contraindications and Safety Summary for Prescribers

Symbravo carries a Boxed Warning for serious cardiovascular thrombotic events and serious GI adverse events. Key contraindications include: ischemic cardiovascular disease, CABG setting, use of ergotamines or other triptans within 24 hours, MAO-A inhibitor use within 14 days, aspirin-sensitive asthma, and moderate-to-severe renal insufficiency with volume depletion risk. The most common adverse reactions in trials were dizziness and somnolence. Symbravo is not indicated for cluster headache or preventive migraine treatment.

When to Consider Alternatives to Symbravo

For patients who cannot access Symbravo or have contraindications, see our guide on alternatives to Symbravo for a clinical comparison of gepants, ditans, and other triptan/NSAID combinations.